Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus paclitaxel/carboplatin in advanced or recurrent endometrial cancer
KCT0006980Phase 3Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in endometrial cancer (EC), sponsored by National Cancer Institute. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on KCT0006980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006980.